Novel surface targets and serum biomarkers from the ovarian cancer vasculature

Cancer Biology and Therapy

Volumn 12, Issue 3, 2011, Pages 169-180

  Sasaroli, Dimitra ^a,b   Gimotty, Phyllis A ^a   Pathak, Harsh B ^c   Hammond, Rachel ^a   Kougioumtzidou, Eleni ^a,b   Katsaros, Dionyssis ^d   Buckanovich, Ron ^a,e   Devarajan, Karthik ^c   Sandaltzopoulos, Raphael ^b   Godwin, Andrew K ^c   Scholler, Nathalie ^a   Coukos, George ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^c FOX CHASE CANCER CENTER   (United States)

^d UNIVERSITY OF TURIN   (Italy)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Biomarkers; Cancer; Diagnostics; Expression; Ovarian; Profiling; Serum; Vascular

Indexed keywords

ADAM PROTEIN; BETA ACTIN; CD31 ANTIGEN; CELL CYCLE PROTEIN; TUMOR MARKER;

ARTICLE; CANCER TISSUE; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOLECULAR IMAGING; MOLECULARLY TARGETED THERAPY; OVARY CANCER; PROTEIN BLOOD LEVEL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

ADAM PROTEINS; ANTIGENS, CD; CELL ADHESION MOLECULES; CELL HYPOXIA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEMBRANE PROTEINS; NEOPLASM PROTEINS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RECEPTORS, TUMOR NECROSIS FACTOR; REFERENCE VALUES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 79961232009     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.12.3.16260     Document Type: Article

References (36)

1. Buckanovich RJ, Sasaroli D, O'Brien-Jenkins A, Botbyl J, Hammond R, Katsaros D, et al. Tumor vascular proteins as biomarkers in ovarian cancer. J Clin Oncol 2007; 25:852-61; DOI: 10.1200/JCO.2006.08.8583.
2. Bhati R, Patterson C, Livasy CA, Fan C, Ketelsen D, Hu Z, et al. Molecular characterization of human breast tumor vascular cells. Am J Pathol 2008; 172:1381-90; DOI: 10.2353/ajpath.2008.070988.
3. Lu C, Bonome T, Li Y, Kamat AA, Han LY, Schmandt R, et al. Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res 2007; 67:1757-68; DOI: 10.1158/0008-5472.CAN-06-3700.
4. Madden SL, Cook BP, Nacht M, Weber WD, Callahan MR, Jiang Y, et al. Vascular gene expression in nonneoplastic and malignant brain. Am J Pathol 2004; 165:601-8; DOI: 10.1016/S0002-9440(10)63324-X.
5. Parker BS, Argani P, Cook BP, Liangfeng H, Chartrand SD, Zhang M, et al. Alterations in vascular gene expression in invasive breast carcinoma. Cancer Res 2004; 64:7857-66; DOI: 10.1158/0008-5472.CAN- 04-1976.
6. St. Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, et al. Genes expressed in human tumor endothelium. Science 2000; 289:1197-202; DOI: 10.1126/science.289.5482.1197.
7. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29:15-8.
8. Folkman J. Angiogenesis. Annu Rev Med 2006; 57:1-18; DOI: 10.1146/annurev.med.57.121304.131306.
9. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86:353-64; DOI: 10.1016/S0092-8674(00) 80108-7.
10. Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem JL, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009; 27:2231-7; DOI: 10.1200/JCO.2008.20.0238.
11. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42; DOI: 10.1056/NEJMoa032691.
12. Belani CP, Ramalingam S. Bevacizumab extends survival for patients with nonsquamous non-small-cell lung cancer. Clin Lung Cancer 2005; 6:267-8. (Pubitemid 40852409)
13. Miller JC, Pien HH, Sahani D, Sorensen AG, Thrall JH. Imaging angiogenesis: applications and potential for drug development. J Natl Cancer Inst 2005; 97:172-87; DOI: 10.1093/jnci/dji023.
14. Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer 2005; 5:436-46; DOI: 10.1038/nrc1627.
15. Siemann DW, Chaplin DJ, Horsman MR. Vasculartargeting therapies for treatment of malignant disease. Cancer 2004; 100:2491-9; DOI: 10.1002/cncr.20299.
16. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005; 5:423-35; DOI: 10.1038/nrc1628.
17. Jennewein M, Lewis MA, Zhao D, Tsyganov E, Slavine N, He J, et al. Vascular imaging of solid tumors in rats with a radioactive arsenic-labeled antibody that binds exposed phosphatidylserine. Clin Cancer Res 2008; 14:1377-85; DOI: 10.1158/1078-0432.CCR-07-1516.
18. Pasqualini R, Moeller BJ, Arap W. Leveraging molecular heterogeneity of the vascular endothelium for targeted drug delivery and imaging. Semin Thromb Hemost 2010; 36:343-51; DOI: 10.1055/s-0030-1253456.
19. Bieker R, Kessler T, Schwoppe C, Padro T, Persigehl T, Bremer C, et al. Infarction of tumor vessels by NGR-peptide- directed targeting of tissue factor: experimental results and first-in-man experience. Blood 2009; 113:5019-27; DOI: 10.1182/blood-2008-04-150318.
20. Carson-Walter EB, Watkins DN, Nanda A, Vogelstein B, Kinzler KW, St. Croix B. Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res 2001; 61:6649-55. (Pubitemid 32896479)
21. Castellani P, Viale G, Dorcaratto A, Nicolo G, Kaczmarek J, Querze G, et al. The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int J Cancer 1994; 59:612-8; DOI: 10.1002/ijc.2910590507.
22. Reinmuth N, Liu W, Ahmad SA, Fan F, Stoeltzing O, Parikh AA, et al. Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res 2003; 63:2079-87. (Pubitemid 36538610)
23. Buckanovich RJ, Sasaroli D, O'Brien-Jenkins A, Botbyl J, Conejo-Garcia JR, Benencia F, et al. Use of immuno- LCM to identify the in situ expression profile of cellular constituents of the tumor microenvironment. Cancer Biol Ther 2006; 5:635-42; DOI: 10.4161/ cbt.5.6.2676.
24. García-Vallejo JJ, Van Dijk W, Van Het Hof B, Van Die I, Engelse MA, Van Hinsbergh VW, et al. Activation of human endothelial cells by tumor necrosis factoralpha results in profound changes in the expression of glycosylation-related genes. J Cell Physiol 2006; 206:203-10; DOI: 10.1002/jcp.20458.
25. Peng Y, Li J, Geng M. The glycan profile of endothelial cells in the present of tumor-conditioned medium and potential roles of beta-1,6-GlcNAc branching on HUVEC conformation. Mol Cell Biochem 2010; 340:143-52; DOI: 10.1007/s11010-010-0411-z.
26. Béchard D, Scherpereel A, Hammad H, Gentina T, Tsicopoulos A, Aumercier M, et al. Human endothelial- cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. J Immunol 2001; 167:3099-106. (Pubitemid 32852547)
27. Bhatt AS, Erdjument-Bromage H, Tempst P, Craik CS, Moasser MM. Adhesion signaling by a novel mitotic substrate of src kinases. Oncogene 2005; 24:5333-43; DOI: 10.1038/sj.onc.1208582.
28. Osada A, Kiyozumi D, Tsutsui K, Ono Y, Weber CN, Sugimoto N, et al. Expression of MAEG, a novel basement membrane protein, in mouse hair follicle morphogenesis. Exp Cell Res 2005; 303:148-59; DOI: 10.1016/j.yexcr.2004.04.053.
29. Asakura M, Kitakaze M, Takashima S, Liao Y, Ishikura F, Yoshinaka T, et al. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med 2002; 8:35-40; DOI: 10.1038/nm0102-35.
30. Milner CM, Higman VA, Day AJ. TSG-6: a pluripotent inflammatory mediator? Biochem Soc Trans 2006; 34:446-50; DOI: 10.1042/BST0340446.
31. Uhland K. Matriptase and its putative role in cancer. Cell Mol Life Sci 2006; 63:2968-78; DOI: 10.1007/ s00018-006-6298-x.
32. Uekita T, Tanaka M, Takigahira M, Miyazawa Y, Nakanishi Y, Kanai Y, et al. CUB-domain-containing protein 1 regulates peritoneal dissemination of gastric scirrhous carcinoma. Am J Pathol 2008; 172:1729-39; DOI: 10.2353/ajpath.2008.070981.
33. Conejo-Garcia JR, Buckanovich RJ, Benencia F, Courreges MC, Rubin SC, Carroll RG, et al. Vascular leukocytes contribute to tumor vascularization. Blood 2005; 105:679-81; DOI: 10.1182/blood-2004-05-1906.
34. Davies G, Cunnick GH, Mansel RE, Mason MD, Jiang WG. Levels of expression of endothelial markers specific to tumour-associated endothelial cells and their correlation with prognosis in patients with breast cancer. Clin Exp Metastasis 2004; 21:31-7; DOI: 10.1023/B:CLIN.0000017168.83616.d0.
35. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005; 438:820-7; DOI: 10.1038/nature04186.
36. Conejo-Garcia JR, Benencia F, Courreges MC, Kang E, Mohamed-Hadley A, Buckanovich RJ, et al. Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-.A. Nat Med 2004; 10:950-8; DOI: 10.1038/nm1097.